These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 20101719)

  • 1. Vaccination as a therapeutic approach to Alzheimer's disease.
    Wisniewski T; Boutajangout A
    Mt Sinai J Med; 2010; 77(1):17-31. PubMed ID: 20101719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.
    Wisniewski T; Boutajangout A
    Brain Struct Funct; 2010 Mar; 214(2-3):201-18. PubMed ID: 20012091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for Alzheimer's disease.
    Wisniewski T; Goñi F
    Biochem Pharmacol; 2014 Apr; 88(4):499-507. PubMed ID: 24412277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Murine models of Alzheimer's disease and their use in developing immunotherapies.
    Wisniewski T; Sigurdsson EM
    Biochim Biophys Acta; 2010 Oct; 1802(10):847-59. PubMed ID: 20471477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD mice.
    Rasool S; Martinez-Coria H; Wu JW; LaFerla F; Glabe CG
    J Neurochem; 2013 Aug; 126(4):473-82. PubMed ID: 23672786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology.
    Serrano-Pozo A; William CM; Ferrer I; Uro-Coste E; Delisle MB; Maurage CA; Hock C; Nitsch RM; Masliah E; Growdon JH; Frosch MP; Hyman BT
    Brain; 2010 May; 133(Pt 5):1312-27. PubMed ID: 20360050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulation targeting of both Aβ and tau pathological conformers ameliorates Alzheimer's disease pathology in TgSwDI and 3xTg mouse models.
    Goñi F; Herline K; Peyser D; Wong K; Ji Y; Sun Y; Mehta P; Wisniewski T
    J Neuroinflammation; 2013 Dec; 10():150. PubMed ID: 24330773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tau-based therapeutic approaches for Alzheimer's disease - a mini-review.
    Boutajangout A; Wisniewski T
    Gerontology; 2014; 60(5):381-5. PubMed ID: 24732638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active full-length DNA Aβ
    Rosenberg RN; Fu M; Lambracht-Washington D
    Alzheimers Res Ther; 2018 Nov; 10(1):115. PubMed ID: 30454039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel immunological approaches for the treatment of Alzheimer's disease.
    Sabharwal P; Wisniewski T
    Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi; 2014; 14(3):139-151. PubMed ID: 25429302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-β-sheet conformation monoclonal antibody reduces tau and Aβ oligomer pathology in an Alzheimer's disease model.
    Goñi F; Martá-Ariza M; Herline K; Peyser D; Boutajangout A; Mehta P; Drummond E; Prelli F; Wisniewski T
    Alzheimers Res Ther; 2018 Jan; 10(1):10. PubMed ID: 29378642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model.
    Herline K; Prelli F; Mehta P; MacMurray C; Goñi F; Wisniewski T
    Alzheimers Res Ther; 2018 Jun; 10(1):54. PubMed ID: 29914551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomodulation targeting abnormal protein conformation reduces pathology in a mouse model of Alzheimer's disease.
    Goñi F; Prelli F; Ji Y; Scholtzova H; Yang J; Sun Y; Liang FX; Kascsak R; Kascsak R; Mehta P; Wisniewski T
    PLoS One; 2010 Oct; 5(10):e13391. PubMed ID: 20967130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent neuropathological effects 14 years following amyloid-β immunization in Alzheimer's disease.
    Nicoll JAR; Buckland GR; Harrison CH; Page A; Harris S; Love S; Neal JW; Holmes C; Boche D
    Brain; 2019 Jul; 142(7):2113-2126. PubMed ID: 31157360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapeutic approaches for Alzheimer's disease.
    Wisniewski T; Goñi F
    Neuron; 2015 Mar; 85(6):1162-76. PubMed ID: 25789753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advancements toward therapeutic vaccines against Alzheimer's disease.
    Herline K; Drummond E; Wisniewski T
    Expert Rev Vaccines; 2018 Aug; 17(8):707-721. PubMed ID: 30005578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models.
    Götz J; Schild A; Hoerndli F; Pennanen L
    Int J Dev Neurosci; 2004 Nov; 22(7):453-65. PubMed ID: 15465275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy for Alzheimer's disease.
    Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
    Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innate immunity stimulation via CpG oligodeoxynucleotides ameliorates Alzheimer's disease pathology in aged squirrel monkeys.
    Patel AG; Nehete PN; Krivoshik SR; Pei X; Cho EL; Nehete BP; Ramani MD; Shao Y; Williams LE; Wisniewski T; Scholtzova H
    Brain; 2021 Aug; 144(7):2146-2165. PubMed ID: 34128045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.